

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Application Number		10/607,909			
Filing Date		June 27, 2003			
First Named Inventor		Sommadosi <i>et al.</i>			
Group Art Unit		1646			
Examiner Name		Unassigned			
Attorney Docket Number		06171.105088 IDX 1031			

OIPE JC
FEB 10 2004
PATENT & TRADEMARK OFFICE

Sheet	1	of	7
-------	---	----	---

3405786 1

U.S. PATENT DOCUMENTS							
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages/Relevant Figures Appear	T ⁶
		Number	Kind Code (if known)				
TM	AA	3,798,209		Wilkowski, <i>et al.</i>	03-19-1974		
	AB	RE29,835		Witkowski <i>et al.</i>	11-14-1978		
	AC	4,522,811		Eppstein <i>et al.</i>	06-11-1985		
	AD	4,957,924		Beauchamp	09-18-1990		
	AE	5,149,794		Yatvin <i>et al.</i>	09-22-1992		
	AF	5,157,027		Biller <i>et al.</i>	10-20-1992		
	AG	5,194,654		Hostetler <i>et al.</i>	03-16-1993		
	AH	5,223,263		Hostetler <i>et al.</i>	06-29-1993		
	AI	5,256,641		Yatvin <i>et al.</i>	10-26-1993		
	AJ	5,411,947		Hostetler <i>et al.</i>	05-02-1995		
	AK	5,463,092		Hostetler <i>et al.</i>	10-31-1995		
	AL	5,543,389		Yatvin <i>et al.</i>	08-06-1996		
	AM	5,543,390		Yatvin <i>et al.</i>	08-06-1996		
	AN	5,543,391		Yatvin <i>et al.</i>	08-06-1996		
	AO	5,554,728		Basava <i>et al.</i>	09-10-1996		
TM	AP	6,312,662	B1	Erion <i>et al.</i>	11-06-2001		

FOREIGN PATENT DOCUMENTS								
Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages/ Relevant Figures Appear	T ⁶
		Office ³	Number	Kind Code ² (if known)				
TM	AQ	DE	3,512,781	A1	Soc. Nat. Elf Aquitaine	10-17-1985		
TM	AR	EP	0,180,276	B1	Stamicarbon B.V.	12-19-1988		
TM	AS	EP	0,350,287	B1	Chimerix	09-27-2000		
TM	AT	EP	0,650,371	B1	State of Oregon	11-15-2000		
TM	AU	WO	89/02733	A1	Regents of the Univ. of California	04-06-1989		
TM	AV	WO	90/00555	A1	Vical Inc.	01-25-1990		
TM	AW	WO	91/16920	A1	Vical Inc.	11-14-1991		

Examiner Signature	/Traviss McIntosh III/ (04/28/2006)	Date Considered	04/28/2006
-----------------------	-------------------------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/607,909
				Filing Date	June 27, 2003
				First Named Inventor	Sommadossi et al.
				Group Art Unit	1646
				Examiner Name	Unassigned
				Attorney Docket Number	06171.105088 IDX 1031
2		of		7	

3403786 1

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages/ Relevant Figures Appear	T ⁴
		Office ³	Number	Kind Code ² (if known)				
TM	BA	WO	91/18914	A1	Vical Inc.	12-12-1991		
	BB	WO	91/19721	A1	Glazier	12-26-1991		
	BC	WO	93/00910	A1	Vical Inc.	01-21-1993		
	BD	WO	94/26273	A1	Hostetler	11-24-1994		
	BE	WO	96/15132	A1	Regents of the Univ. of California	05-23-1996		
	BF	WO	99/15194	A1	Schering Corporation	04-01-1999		
	BG	WO	99/43691	A1	Emory; U. Georgia Res. Found.	09-02-1999		
	BH	WO	99/45016	A2	Metabasis Therapeutics Inc.	09-10-1999		
	BI	WO	99/59621	A1	Schering Corporation	11-25-1999		
	BJ	WO	99/64016	A1	Hoffman-La Roche AG	12-16-1999		
	BK	WO	00/24355	A1	Smith & Nephew Kinetic	05-04-2000		
	BL	WO	00/37110	A2&3	Schering Corporation	06-29-2000		
	BM	WO	00/52015	A2&3	Metabasis Therapeutics	09-08-2000		
	BN	WO	01/18013	A1	Metabasis Therapeutics	03-15-2001		
	BO	WO	01/32153	A2	Biochem Pharma	10-05-2001		
	BP	WO	01/47935	A2&3	Metabasis Therapeutics	07-05-2001		
	BQ	WO	01/60315	A2	Biochem Pharma	08-23-2001		
	BR	WO	01/79246	A2&3	Pharmasset	10-25-2001		
	BS	WO	01/81359	A1	Schering Corporation	11-01-2000		
	BT	WO	01/90121	A2&3	Novirio (Idenix); Univ. ... Cagliari	11-29-2000		
	BU	WO	01/92282	A2&3	Novirio (Idenix); Univ. ... Cagliari	06-12-2001		
	BV	WO	01/96353	A2&3	Novirio Pharm. (Idenix); C.N.R.S.	21-20-2001		
	BW	WO	02/057287	A2&3	Merck; Isis Pharmaceuticals	07-25-2002		
	BX	WO	02/057425	A2	Merck; Isis Pharmaceuticals	07-25-2002		
	BY	WO	02/18404	A2&3	Hoffman-La Roche AG	03-07-2002		
	BZ	WO	02/32414	A2&3	Schering Corporation	04-25-2002		
✓	BAA	WO	02/32920	A2	Pharmasset	04-25-2002		
	BAB	WO	02/48165	A2&3	Pharmasset	06-20-2002		
TM	BAC	WO	03/024461	A1	Schering Corporation	03-27-2003		

Examiner Signature	/Traviss McIntosh III/ (04/28/2006)	Date Considered	04/28/2006
--------------------	-------------------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/607,909
				Filing Date	June 27, 2003
				First Named Inventor	Sommadossi <i>et al.</i>
				Group Art Unit	1646
				Examiner Name	Unassigned
	3	of	7	Attorney Docket Number	06171.105088 IDX 1031



3405786 1

FOREIGN PATENT DOCUMENTS								
Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages/ Relevant Figures Appear	T ⁶
		Office ³	Number	Kind Code ³ (if known)				
TM	CA	WO	04/003138	A2	Merck & Co., Isis Pharmaceutical	01-08-2004		
TM	CB	WO	04/007512	A2	Merck & Co., Isis Pharmaceutical	01-22-2004		
TM	CC	WO	04/009020	A2	Merck & Co., Isis Pharmaceutical	01-29-2004		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS								
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						T ⁶
TM	CD	BAGINSKI, S. G. <i>et al.</i> , "Mechanism of action of a pestivirus antiviral compound," <i>PNAS USA</i> , 97(14): 7981-7986 (2000).						
	CE	BATTAGLIA, A.M. <i>et al.</i> , "Combination Therapy with Interferon and Ribavirin in the Treatment of Chronic Hepatitis C Infection", <i>Ann. Pharmacother.</i> , 34:487-494 (2000).						
	CF	BERENGUER, M. <i>et al.</i> , "Hepatitis C virus in the transplant setting", <i>Antivir. Ther.</i> , 3 (Suppl 3):125-136 (1998).						
	CG	BERMAN, E. <i>et al.</i> , "Synergistic cytotoxic effect of azidothymidine and recombinant interferon alpha on normal human bone marrow progenitor cells," <i>Blood</i> , 74(4):1281-1286 (1989)						
	CH	BHAT <i>et al.</i> (Oral Session V, Hepatitis C Virus, Flaviviridae, 2003 (Oral Session V, Hepatitis C Virus, Flaviviridae; 16 th International Conference on Antiviral Research (April 27, 2003, Savannah, Ga.); p A75).						
	CI	BROWNE, M.J., <i>et al.</i> , "2',3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-Related Complex: A Phase I trial," <i>J. Infect. Dis.</i> , 167(1):21-29 (1993).						
	CJ	COLACINO, J. M., "Review article: Mechanisms for the anti-hepatitis B virus activity and mitochondrial toxicity of fialuridine (FIAU)," <i>Antiviral Res.</i> , 29(2-3): 125-39 (1996).						
	CK	CUI, L., <i>et al.</i> , "Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-β-D-arabinofuranosyl)-5-iodouracil in human liver cells," <i>J. Clin. Invest.</i> , 95:555-563 (1995).						
	CL	DAVIS, G.L., "Current therapy for chronic Hepatitis C," <i>Gastroenterology</i> 118:S104-S114 (2000).						
	CM	De FRANCESCO, R., <i>et al.</i> , "Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase," <i>Antiviral Research</i> , 58: 1-16 (2003).						
TM	CN	De LOMBAERT, S., <i>et al.</i> , "N-Phosphonomethyl dipeptides and their phosphonate prodrugs, a new generation of neutral endopeptidase (NEP, EC 3.4.24.11) inhibitors," <i>J. Med. Chem.</i> , 37:498-511 (1994).						

Examiner Signature	/Traviss McIntosh III/ (04/28/2006)	Date Considered	04/28/2006
--------------------	-------------------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/607,909
		Filing Date	June 27, 2003
		First Named Inventor	Sommadossi <i>et al.</i>
		Group Art Unit	1646
		Examiner Name	Unassigned
		Attorney Docket Number	06171.105088 IDX 1031
4	of	7	



3403786 1

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
TM	DA	DORNSIFE, R.E., <i>et al.</i> , "In vitro potency of inhibition by antiviral drugs of hematopoietic progenitor colony formation correlates with exposure at hemotoxic levels in Human Immunodeficiency Virus-positive humans," <i>Antimicrob. Agents Chemother.</i> , 40(2):514-519 (1996).	
	DB	DYMOCK, B.W., <i>et al.</i> , "Review: Novel approaches to the treatment of hepatitis C virus infection," <i>Antiviral Chemistry & Chemotherapy</i> , 11(2):79-95 (2000).	
	DC	ELDRUP <i>et al.</i> (Oral Session V, Hepatitis C Virus, Flaviviridae; 16 th International Conference on Antiviral Research (April 27, 2003, Savannah, Ga.).	
	DD	FARKAS, J., <i>et al.</i> , "Nucleic acid components and their analogues. XCIV. Synthesis of 6-amino-9-(1-deoxy-β-D-psicofuranosyl)purine", <i>Collect. Czech. Chem. Commun.</i> 32:2663-2667 (1967).	
	DE	FARKAS, J., <i>et al.</i> , "Nucleic acid components and their analogues. LXXIX. Synthesis of methyl 1-deoxy-D-psicofuranosides substituted at C ₍₁₎ with halo atoms or a mercapto group," <i>Collect. Czech. Chem. Commun.</i> , 31:1535-1543 (1996).	
	DF	FARQUHAR, D., <i>et al.</i> , "Synthesis and biological evaluation of neutral derivatives of 3-fluoro-2'-deoxyuridine 5'-phosphate," <i>J. Med. Chem.</i> 26: 1153 (1983);	
	DG	FARQUHAR, D., <i>et al.</i> , "Synthesis and biological evaluation of 9-[5'-(2-oxo-1,3,2-oxazaphosphorinan-2-yl)-β-D-arabinosyl]adenine and 9-[5'-(2-oxo-1,3,2-dioxazaphosphorinan-2-yl)-β-D-arabinosyl]adenine: Potential neutral precursors of 9-[β-D-arabinofuranosyl]adenine 5'-monophosphate," <i>J. Med. Chem.</i> 28:1358-1381 (1985).	
	DH	FERRARI R., <i>et al.</i> , "Characterization of soluble hepatitis C virus RNA-dependent RNA polymerase expressed in <i>Escherichia coli</i> ," <i>Journal of Virology</i> , 73(2), 1649-1654 (1999).	
	DI	FISCHL, M.A., <i>et al.</i> , "Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy," <i>Ann. Intern. Med.</i> , 18(10):762-769 (1993).	
	DJ	FREED, J.J., <i>et al.</i> , "Evidence for acyloxymethyl esters of pyrimidine 5'-deoxyribonucleotides as extracellular sources of active 5'-deoxyribonucleotides in cultured cells," <i>Biochemical Pharmacology</i> . 38:3193-3198 (1989).	
	DK	GUNIC, E., <i>et al.</i> , "Synthesis and cytotoxicity of 4'-C-and 5'-C-substituted Toyocamycins," <i>Bioorg. Med. Chem.</i> , 9:163-170 (2001).	
✓	DL	HARRY-O'KURU, R.E., J.M. Smith, and M.S. Wolfe, "A short, flexible route toward 2'-C-branched ribonucleosides", <i>J.Org. Chem.</i> 62, 1754-1759 (1997). (Scheme 11).	
TM	DM	HOSTETLER, K.Y., <i>et al.</i> , "Synthesis and antiretroviral activity of phospholipids analogs of azidothymidine and other antiviral nucleosides," <i>J. Biol. Chem.</i> , 265:6112-6117 (1990)	

Examiner Signature	/Traviss McIntosh III/ (04/28/2006)	Date Considered	04/28/2006
--------------------	-------------------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/607,909		
		Filing Date	June 27, 2003		
		First Named Inventor	Sommadossi et al		
		Group Art Unit	1646		
		Examiner Name	Unassigned		
	5	of	7	Attorney Docket Number	06171.105088 IDX 1031



3405786 /

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
TM	EA	HOSTETLER, K.Y., et al., "Greatly enhanced inhibition of Human Immunodeficiency Virus Type I replication in CEM and HT4-6C cells by 3'-deoxythymidine diphosphate dimyristoylglycerol, a lipid prodrug of 3'-deoxythymidine," <i>Antimicrob. Agents Chemother.</i> , 36:2025-2029 (September 1992).	
	EB	HUNSTON, R.N., et al., "Synthesis and biological properties of some cyclic phosphotriesters derived from 2'-deoxy-5-fluorouridine," <i>J. Med. Chem.</i> 27:440-444 (1984).	
	EC	JONES, G. H.; Moffatt, J. G., <i>Methods in Carbohydrate Chemistry</i> ; Whisler, R. L. and Moffatt, J. L. Eds; Academic Press: New York, 1972; 315-322	
	ED	JONES, G. H., et al., "4'-substituted nucleosides. 5. Hydroxymethylation of nucleoside 5'-aldehydes," <i>J. Org. Chem.</i> , 44:1309-1317 (1979).	
	EE	KHAMNEI, S., "Neighboring group catalysis in the design of nucleotide prodrugs," <i>J. Med. Chem.</i> , 39:4109-4115 (1996).	
	EF	KUCERA, L.S., et al., "Novel membrane-interactive ether lipid analogs that inhibit infectious HIV-1 production and induce defective virus formation," <i>AIDS Res. Hum. Retro Viruses</i> , 6:491-501 (1990).	
	EG	KURTZBERG J., et al., "Differential toxicity of carbosvir and AZT to human bone marrow hematopoietic progenitor cells in vitro," <i>Exp. Hematol.</i> , 18(10):1094-1096 (1990).	
	EH	LEONARD, N. J., et al., "5-Amino-5-deoxyribose derivatives. Synthesis and use in the preparation of "reversed" nucleosides" <i>J. Heterocycl. Chem.</i> , 3:485-489 (December 1966).	
	EI	LERZA, R., et al., "In vitro synergistic inhibition of human bone marrow hemopoietic progenitor growth by a 3'-azido-3'-deoxy-thymidine, 2',3'-dideoxycytidine combination," <i>Exp. Hematol.</i> , 25(3):252-255 (1997).	
	EJ	LEWIS W., et al., "Zidovudine induces molecular, biochemical, and ultrastructural changes in rat skeletal muscle mitochondria," <i>J. Clin. Invest.</i> , 89(4):1354-1360 (1992).	
	EK	LEWIS, L. D., et al., "Ultrastructural changes associated with reduced mitochondrial DNA and impaired mitochondrial function in the presence of 2'3'-dideoxycytidine," <i>Antimicrob. Agents Chemother.</i> , 36(9):2061-2065 (1992).	
	EL	LEWIS, W., et al., "Fialuridine and its metabolites inhibit DNA polymerase γ at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts," <i>Proceedings of the National Academy of Sciences, USA</i> , 93(8): 3592-7 (1996).	
✓	EM	LOHMANN V., et al., "Biochemical and kinetic analyses of NS5B RNA-dependent RNA polymerase of the Hepatitis C virus," <i>Virology</i> , 249, 108-118 (1998).	
TM	EN	LUH, T.-Y., et al., "A convenient method for the selective esterification of amino-alcohols," <i>Synthetic Communications</i> , 8(5):327-333 (1978).	

Examiner Signature	/Traviss McIntosh III/ (04/28/2006)	Date Considered	04/28/2006
--------------------	-------------------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/607,909
				Filing Date	June 27, 2003
				First Named Inventor	Sommadossi <i>et al.</i>
				Group Art Unit	1646
				Examiner Name	Unassigned
6	of	7	Attorney Docket Number	06171.105088 IDX 1031	



3403786 1

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁴
TM	FA	MCCORMICK, J., <i>et al.</i> , "Structure and total synthesis of HF-7, a neuroactive glyconucleoside disulfate from the funnel-web spider <i>Hololena curta</i> ," <i>J. Am. Chem. Soc.</i> , 121(24), 5661-5664 (1999).	
	FB	MCKENZIE, R., <i>et al.</i> , "Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B," <i>N. Engl. J. Med.</i> , 333(17):1099-1105 (1995).	
	FC	MEIER, C., <i>et al.</i> , "Cyclic saligenyl phosphotriesters of 2',3'-dideoxy-2',3'-didehydrothymidine (d4T) – A new pro-nucleic approach." <i>Bioorganic & Med. Chem. Letters</i> 7(2):99-104 (1997).	
	FD	MEDINA, D. J., <i>et al.</i> , "Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-Human Immunodeficiency Virus dideoxynucleosides," <i>Antimicrob. Agents Chemother.</i> , 38(8):1824-8 (1994).	
	FE	MEYER, R.B., Jr., <i>et al.</i> , "2'-O-Acyl-6-thioinosine cyclic 3',5'-phosphates as prodrugs of thioinosinic acid," <i>J. Med. Chem.</i> 22: 811-815 (1979).	
	FF	NEIDLEIN, R., <i>et al.</i> , "Mild preparation of 1-benzyluxyiminophosphonic dichlorides: Application to the synthesis of cyclic phosphonic diesters and cyclic monoester amides," <i>Heterocycles</i> 35:1185-1203 (1993).	
	FG	NUTT, R.F., <i>et al.</i> , "Branched-chain sugar nucleosides. III. 3'-C-methyladenine", <i>J. Org. Chem.</i> , 33:1789-1795 (1968).	
	FH	OLSEN, <i>et al.</i> (Oral Session V, Hepatitis C Virus, Flaviviridae; 16 th International Conference on Antiviral Research (April 27, 2003, Savannah, Ga.) p A76).	
	FI	PAN-ZHOU, X-R, <i>et al.</i> , "Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells," <i>Antimicrob. Agents Chemother.</i> 44:496-503 (2000).	
	FJ	PIANTADOSI, C., <i>et al.</i> , "Synthesis and evaluation of novel ether lipid nucleoside conjugates for anti-HIV-1 activity," <i>J. Med. Chem.</i> 34:1408-1414 (1991).	
	FK	RICHMAN, D.D., <i>et al.</i> , "The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-Related Complex," <i>N. Engl. J. Med.</i> , 317(4):192-197 (1987).	
	FL	SOMMADOSSI J-P, <i>et al.</i> , "Comparison of cytotoxicity of the (-)- and (+)- enantiomer of 2',3'-dideoxy-3'-thiacytidine in normal human bone marrow progenitor cells," <i>Biochemical Pharmacology</i> 44(10):1921-1925 (1992).	
	FM	SOMMADOSSI J-P, <i>et al.</i> , "Toxicity of 3'-azido-3'-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro," <i>Antimicrobial Agents and Chemotherapy</i> , 31:452-454 (1987).	
TM	FN	STARRETT, J.E.Jr., <i>et al.</i> , "Synthesis, oral bioavailability determination, and <i>in vitro</i> evaluation of prodrugs of the antiviral agents 9-(2-(phosphonomethoxy)ethyl]adenine (PMEA)," <i>J. Med. Chem.</i> 37: 1857-1864 (1994).	

Examiner Signature	/Traviss McIntosh III/ (04/28/2006)	Date Considered	04/28/2006
--------------------	-------------------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/607,909	
		Filing Date	June 27, 2003	
		First Named Inventor	Sommadossi <i>et al.</i>	
		Group Art Unit	1646	
		Examiner Name	Unassigned	
7	of	7	Attorney Docket Number	06171.105088 IDX 1031



3405786 1

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
TM	GA	WEINBERG, R.S., <i>et al.</i> , "Effect of antiviral drugs and hematopoietic growth factors on <i>in vitro</i> erythropoiesis," <i>Mt. Sinai J. Med.</i> 1998;65(1):5-13.	
TM	GB	YARCHOAN, R., <i>et al.</i> , "Long-term toxicity / activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex," <i>The Lancet</i> , 336(8714):526-529 (1990).	
TM	GC	YOSHIDA Y, <i>et al.</i> , "Reversal of azidothymidine-induced bone marrow suppression by 2',3'-dideoxythymidine as studied by hemopoietic clonal culture," <i>AIDS Res. Hum. Retroviruses</i> , 6(7):929-932 (1990).	
TM	GD	ZON, G., "Cyclophosphamide Analogues," Chapter 4 in <i>Progress in Medicinal Chemistry</i> , Vol. 19, G.P. Ellis and G.B. West, Eds., pp. 205-246 (1982).	


3405786 1

Examiner Signature	/Traviss McIntosh III/ (04/28/2006)	Date Considered	04/28/2006
--------------------	-------------------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



APR 02 2006

Please type (+) inside this box →



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

4

Complete if Known

Application Number	10/607,909
Filing Date	June 27, 2003
First Named Inventor	Sommadossi <i>et al.</i>
Group Art Unit	1623
Examiner Name	Traviss C. McIntosh III
Attorney Docket Number	06171.105088 IDX 1031

3405786 1

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages/Relevant Figures Appear	T ⁶
		Number	Kind Code (if known)				
TM	AA	6,348,587		Schinazi <i>et al.</i>	02-19-2002		
	AB	2002/0095033		Ramasamy <i>et al.</i>	07-18-2002		
	AD	6,495,677		Ramasamy <i>et al.</i>	12-17-2002		
	AE	2002/0198171		Schinazi <i>et al.</i>	12-26-2002		
	AF	2003/0008841		Devos <i>et al.</i>	01-09-2003		
	AH	6,573,248		Ramasamy <i>et al.</i>	06-03-2003		
	AI	2003/0225029		Stuyver <i>et al.</i>	12-04-2003		
	AJ	6,660,721		Devos <i>et al.</i>	12-09-2003		
	AL	2004/0002476		Stuyver <i>et al.</i>	01-01-2004		
	AM	2004-0023921		Yao <i>et al.</i>	02-05-2004		
	AN	2004/0059104		Cook <i>et al.</i>	03-25-2004		
	AO	2004/0063658		Roberts <i>et al.</i>	04-01-2004		
	AP	2004/0067901		Bhat <i>et al.</i>	04-08-2004		
	AQ	2004/0072788		Bhat <i>et al.</i>	04-15-2004		
	AR	2004/0110718		Devos <i>et al.</i>	06-10-2004		
	AS	2004/0110717		Bhat <i>et al.</i>	06-10-2004		
	AU	2004/0147464		Roberts <i>et al.</i>	07-29-2004		
	AV	6,777,395		Bhat <i>et al.</i>	08-17-2004		
	AW	6,784,166		Devos <i>et al.</i>	08-31-2004		
	AX	2004/0266722		Devos <i>et al.</i>	12-30-2004		
	AY	2005/0009737		Clark <i>et al.</i>	01-13-2005		
	AZ	6,846,810		Martin <i>et al.</i>	01-25-2005		
	AAA	2005/0119200		Roberts <i>et al.</i>	06-02-2005		
	AAB	6,911,424		Schinazi <i>et al.</i>	06-28-2005		
	AAC	2003/0060400		LaColla <i>et al.</i>	03-27-2003		
TM	AAD	2003/0050229		LaColla <i>et al.</i>	03-13-2003		

3990459

Examiner
Signature

/Traviss McIntosh III/ (04/28/2006)

Date
Considered

04/28/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/607,909
				Filing Date	June 27, 2003
				First Named Inventor	Sommadossi <i>et al.</i>
				Group Art Unit	1623
				Examiner Name	Traviss C. McIntosh III
	2	of	4	Attorney Docket Number	06171.105088 IDX 1031

3405786_1

FOREIGN PATENT DOCUMENTS								
Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages/ Relevant Figures Appear	T ⁶
		Office ³	Number	Kind Code ² (if known)				
TM	BA	WO	03/051899		Girardet <i>et al.</i>	06-26-2003		
↓	BB	WO	03/061385		An <i>et al.</i>	07-31-2003		
	BC	WO	03/061576		An <i>et al.</i>	07-31-2003		
	BD	WO	03/062256		An <i>et al.</i>	07-31-2003		
	BE	WO	03/062257		An <i>et al.</i>	07-31-2003		
	BF	WO	03/062255		Hong <i>et al.</i>	07-31-2003		
	BG	WO	04/000858		Carroll <i>et al.</i>	12-31-2003		
	BH	WO	03/105770		Bhat Balkrishen	12-24-2003		
	BI	WO	06/012440		Wang <i>et al.</i>	02-02-2006		
	BJ	GB	1163 103		Merck	09-04-1969		
	BK	GB	1163 102		Merck	09-04-1969		
	BL	GB	1209 654		Merck	10-21-1970		
	BM	EP	0747 389		Taiho Pharmaceutical Co. Ltd.	12-11-1996		
	BN	FR	1521076		Merck & Co.	04-12-1968		
	BO	JP	06211890		Yamasa Shoyu Co. Ltd	08-02-1994		
	TM	BP	JP	06228186		Yamasa Shoyu Co. Ltd	08-16-1994	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶	
TM	BQ	AWANO, H., <i>et al.</i> , "Nucleosides and nucleotides. Part 144. Synthesis and antiviral activity of 5-substituted (2'S)-2'-deoxy-2'-C-methylcytidines and -uridines," <i>Archiv der Pharmazie</i> , VCH Verlagsgesellschaft mbh, Weinheim, DE. 329 :66-72 (February 1, 1996).		
TM	BR	BEIGELMAN, L.N., <i>et al.</i> , "A general method for synthesis of 3'-C-alkylnucleosides," <i>Nucleic Acids Symp. Ser.</i> , 9:115-118 (1981).		
TM	BS	BIANCO, <i>et al.</i> , "Synthesis of a New Carbocyclic Nucleoside Analog", <i>Tetrahedron Letters</i> , vol. 38. no. 36., Set 8 1997		

Examiner Signature	/Traviss McIntosh III/ (04/28/2006)	Date Considered	04/28/2006
-----------------------	-------------------------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/607,909
		Filing Date	June 27, 2003
		First Named Inventor	Sommadossi <i>et al.</i>
		Group Art Unit	1623
		Examiner Name	Traviss C. McIntosh III
		Attorney Docket Number	06171.105088 IDX 1031
3	of	4	

3405786 1

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁴
TM	CA	CAPPELLACCI, L., <i>et al.</i> , "Ribose-modified nucleosides as ligands for adenosine receptors: Synthesis, conformational analysis, and biological evaluation of 1'-C-methyl adenosine analogues," <i>J. Med. Chem.</i> , 45:1196-1202 (2002).	
	CB	CHIACCHIO, ., <i>et al.</i> , "Steroselective Synthesis of 2'-Amino-2',3'-Dideoxynucleosides by Nitrone 1,3-Dipolar Cycloaddition: A New Efficient Entry Toward d4T and its 2-Methyl Analogue", <i>J. Org. Chem. vol. 64: 28-36 (1999)</i> .	
	CC	CZERNECKI S. <i>et al.</i> , "Synthesis of 2'-deoxy-2'-spirocyclopropyl Cytidine as Potential Inhibitor of Ribonucleotide Diphosphate Reductase", <i>Can. J. Chem.</i> , 71: 413-416 (1993).	
	CD	FEDEROV, I.I., <i>et al.</i> , "3'-C-branched 2'-deoxy-5-methyluridines: Synthesis, enzyme inhibition, and antiviral properties," <i>J. Med. Chem.</i> , 35:4567-4575 (1992).	
	CE	FRANCHETTI, P., <i>et al.</i> , "2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies," <i>J. Med. Chem.</i> , 41(10):1708-1715 (1998).	
	CF	HASSAN, A.E.A., <i>et al.</i> , "Nucleosides and Nucleotides. 156. Chelation-Controlled and Nonchelation-Controlled Diastereofacial Selective Thiophenol Addition Reactions at the 2'-Position of 2'-[(Alkoxy carbonyl)methylene]-2'-deoxyuridines: Conversion of (Z)-2'-[(Alkoxy carbonyl)methylene]-2'-Deoxyuridines into Their (E)-Isomers", <i>J. Org. Chem.</i> , 62: 11-17 (1997).	
	CG	HASSAN, A.E.A., <i>et al.</i> , "Nucleosides and Nucleotides. 151. Conversion of (Z)-2'-(Cyanomethylene)-2'-Deoxyuridines into Their (E)-Isomers via Addition of Thiophenol to the Cyanomethylene Moiety Followed by Oxidative Syn-elimination Reactions", <i>J. Org. Chem.</i> , 61: 6261-6267 (1996).	
	CH	HOSSAIN N., <i>et al.</i> , "Synthesis of 2'- And 3'-Spiro-Isoxazolidine Derivatives of Thymidine & Their Conversions To 2', 3'-Dideoxy-2', 3'-Didehydro-3'-C-Substituted Nucleosides by Radical Promoted Fragmentation", <i>Tetrahedron</i> , 49: 10133-10156 (1993).	
	CI	HATTORI, H., <i>et al.</i> , "Nucleosides and nucleotides. 158.", <i>J. Med. Chem.</i> , 39:5005-5011 (1996).	
	CJ	HREBABECKY, H., <i>et al.</i> , "Nucleic acid components and their analogues. CXLIX. Synthesis of pyrimidine nucleosides derived from 1-deoxy-D-psicose," <i>Collect. Czech. Chem. Commun.</i> , 37:2059-2065 (1972).	
	CK	HREBABECKY, H., <i>et al.</i> "Synthesis of 7- and 9β-D-psicofuranosylguanine and their 1'-deoxy derivatives," <i>Collect. Czech. Chem. Commun.</i> , 39:2115-2123 (1974).	
	CL	JOHNSON, C.R., <i>et al.</i> , "3'-C-Trifluoromethyl ribonucleosides," <i>Nucleosides & Nucleotides</i> , 14(1&2):185-194 (1995).	
✓	CM	LI, Nan.-Sheng., <i>et al.</i> , "2'-C-branched ribonucleosides. 2. Synthesis of 2'-C-β-trifluoromethyl pyrimidine ribonucleosides," <i>Organic Letters</i> , 3(7):1025-1028 (2001).	
TM	CN	MAHMOUDIAN M. <i>et al.</i> , "A Versatile Procedure for the Generation of Nucleoside 5-'Carboxylic Acids Using Nucleoside Oxidase", <i>Tetrahedron</i> , 54: 8171-8182 (1998).	

Examiner Signature	/Traviss McIntosh III/ (04/28/2006)	Date Considered	04/28/2006
--------------------	-------------------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/607,909
		Filing Date	June 27, 2003
		First Named Inventor	Sommadossi <i>et al.</i>
		Group Art Unit	1623
		Examiner Name	Traviss C. McIntosh III
		Attorney Docket Number	06171.105088 IDX 1031
4	of	4	

3403786 1

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁴
TM	DA	MATSUDA, A., <i>et al.</i> , "Radical deoxygenation of <u>tert</u> -alcohols in 2'-branched-chain sugar pyrimidine nucleosides: Synthesis and antileukemic activity of 2'-deoxy-2'(S)-methylcytidine," <i>Chem. Pharm. Bull.</i> , 35(9):3967-3970 (1987).	
	DB	MATSUDA, A., <i>et al.</i> , "Nucleosides and Nucleotides. 94. Radical deoxygenation of <i>tert</i> -alcohols in 1-(2-C-alkylpentofuranosyl)pyrimidines: Synthesis of (2' <i>S</i>)-2'-deoxy-2'-C-methylcytidine, an antileukemic nucleoside," <i>J. Med. Chem.</i> , 34:234-239 (1991).	
	DC	MIKHAILOV, S.N., <i>et al.</i> , "Synthesis and properties of 3'-C-methylnucleosides and their phosphoric esters," <i>Carbohydrate Research</i> , 124:75-96 (1983).	
	DD	MURAL, Y., <i>et al.</i> , "A synthesis and an X-ray analysis of 2'-C-, 3'-C- and 5'-C-methylsangivamycins," <i>Heterocycles</i> , 1(33):391-404 (1992).	
	DE	ONG, S.P., <i>et al.</i> , "Synthesis of 3'-C-methyladenosine and 3'-C-methyluridine diphosphates and their interaction with the ribonucleoside diphosphate reductase from <i>Corynebacterium nephridii</i> ," <i>Biochemistry</i> , 31(45):11210-11215 (1992).	
	DF	ROSENTHAL, A., <i>et al.</i> , "Branched-chain sugar nucleosides. Synthesis of 3'-C-ethyl (and 3'-C-butyl)uridine <i>Carbohydrate Research</i> , 79:235-242 (1980).	
	DG	SCHMIT, C., "Synthesis of 2'-deoxy-2'- α -monofluoromethyl and trifluoromethylnucleosides," <i>Synlett</i> , Thieme Verlag, Stuttgart, DE, (4):241-242 (1994).	
	DH	SHARMA, P.K., <i>et al.</i> , "Synthesis of 3'-trifluoromethyl nucleosides as potential antiviral agents," <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 19(4):757-774 (2000).	
	DI	TRONCHET, J.M.J.; <i>et al.</i> , "72. Synthèse et désamination enzymatique des C-hydroxyméthyl-3'-et C-méthyl-3'-beta-D-xylofuranosyl-9-adenin es," <i>Helv. Chim. Acta</i> , 62:689-695 (1979).	
	DJ	VELAZQUEZ, S., <i>et al.</i> , "Synthesis of [1-[3',5'-bis-O-(<i>tert</i> -butyldimethylsilyl)- β -D-arabino- and β -D-ribofuranosyl] cytosine]-2'-spiro-5''-(4''-amino-1'', 2''-oxathiole-2'', 2''-dioxide). Analogues of the Highly Specific Anti-HIV-1 agent TSAO-T", <i>Tetrahedron</i> , 50: 11013-11022 (1994).	
TM	DK	WOLF, J., <i>et al.</i> , "New 2'-C-branched-chain sugar nucleoside analogs with potential antiviral or antitumor activity," <i>Synthesis</i> , Georg Thieme Verlag, Stuttgart, DE, (8):773-778 (August 1992).	

3405786_1

Examiner Signature	/Traviss McIntosh III/ (04/28/2006)	Date Considered	04/28/2006
--------------------	-------------------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.